Immix Biopharma CEO Rachman buys $4998 in shares

Published 20/06/2025, 14:40
Immix Biopharma CEO Rachman buys $4998 in shares

Immix Biopharma , Inc. (NASDAQ:IMMX) CEO and Chairman Ilya M. Rachman reported purchasing 2,178 shares of common stock on June 18, 2025. The shares were bought at a volume-weighted average price of $2.295, for a total transaction value of $4998. The purchase comes as the stock shows strong momentum, with InvestingPro data showing returns of over 24% in the past year. With analysts setting a $7 price target and the company maintaining a healthy balance sheet with more cash than debt, this insider purchase draws attention.

Following the transaction, Rachman directly owns 1,138,437 shares of Immix Biopharma, Inc., representing a significant stake in the $66.57 million market cap company. Want deeper insights into insider trading patterns and 8 additional key metrics? Check out InvestingPro for comprehensive analysis.

In other recent news, Immix Biopharma, Inc. has reported encouraging interim results from its Phase 1/2 NEXICART-2 clinical trial for NXC-201, a therapy targeting AL Amyloidosis. The trial demonstrated a 70% complete response rate, with no relapses or significant safety concerns to date. Additionally, Immix Biopharma plans to submit a Biologics License Application for FDA approval based on these findings. The company’s NEXICART-2 trial is progressing ahead of schedule, with 14 U.S. sites now actively enrolling patients, marking a significant increase from previous updates. Immix Biopharma has also entered into an At The Market Offering Agreement with Citizens JMP Securities, LLC, allowing the company to sell shares of its common stock at its discretion. Analysts from H.C. Wainwright have reaffirmed their Buy rating for Immix Biopharma stock, following the presentation of trial results at the annual ASCO meeting. The promising trial outcomes have been highlighted as a basis for maintaining a positive outlook on the company’s stock. Immix Biopharma’s NXC-201 has received Regenerative Medicine Advanced Therapy designation and Orphan Drug Designation from the FDA and EMA, respectively, due to its potential impact on treating AL Amyloidosis.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.